Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Golden Finance reported that the board of directors of Nasdaq-listed Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock repurchase plan. The company's CEO Amit Kumar said that the decision on Bitcoin is another way of prudent financial management to achieve higher shareholder value. It is reported that Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: Nearly 4 billion dollars in funds have been bridged from Ethereum to Base
Data: Australia's Monochrome spot Bitcoin ETF holds 258 BTC
Data: Circle has transferred 50 million USDC to CEX
MemeFi is now live on Sui Network, with a 24-hour increase of more than 75%